{"filings":[{"id":92832,"accession_number":"0001493152-26-021105","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"InspireMD Q1 revenue $3.4M (+122% YoY); voluntary recall of CGuard Prime 135 cm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.7M ($0.16/share) vs $11.2M loss a year ago; operating expenses rose to $14.7M.","GAAP gross profit $0.7M (20.2% margin); adjusted gross profit $1.2M (34.1%) excluding $0.5M impairment charge.","Voluntary recall of CGuard Prime 135 cm; expected costs $700K returns + $650K inventory/remediation.","FDA approved IDE for CGUARDIANS III trial of SwitchGuard NPS; CGuard Prime 80 cm TCAR approval expected H2 2026.","Original CGuard FDA approval anticipated Q3 2026; over 625 cumulative procedures with CGuard Prime since launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":3398000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92831,"accession_number":"0001493152-26-020891","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"InspireMD recalls CGuard Prime 135 cm delivery system due to performance issues; withdraws FY2026 revenue guidance","event_type":"regulatory","confidence":"high","bullets":["Voluntary recall of CGuard Prime 135 cm delivery system in US; technical success not met. No safety issues for implanted stent.","FDA approval for original CGuard delivery system expected Q3 2026; delivery system used in over 70,000 cases worldwide.","Withdrawing prior full year 2026 revenue guidance due to temporary halt in US commercialization pending FDA approval.","FDA approved IDE for CGUARDIANS III pivotal study of SwitchGuard NPS for use with CGuard Prime 80 cm in TCAR procedures.","Q1 2026 global unit sales up 53% YoY; US unit sales up 34% QoQ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92830,"accession_number":"0001493152-26-015127","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"InspireMD enters $75M ATM equity facility with BTIG; terminates prior Piper Sandler ATM","event_type":"other_material","confidence":"high","bullets":["Entered Equity Distribution Agreement with BTIG to sell up to $75M of common stock via ATM offering.","Terminated prior ATM with Piper Sandler; 1,361,519 shares had been sold under that facility.","Proceeds intended for R&D, sales/marketing, working capital, and general corporate purposes.","BTIG receives commission up to 3% of gross proceeds from sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103990,"accession_number":"0001493152-26-010791","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"InspireMD reports Q4 revenue $3.1M (+62% YoY); guides FY2026 rev $13-15M","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $3.1M, up 62% YoY; U.S. rev $0.9M (sequential +74%)","Gross margin improved to 37.5% from 24.1% YoY; net loss $11.8M ($0.14/share)","Full year 2025 rev $9.0M (+28% YoY); net loss $48.8M","Cash and securities $54.2M at Dec 31, 2025 vs $34.6M year earlier","FY2026 revenue guidance $13-15M (45-65% growth); PMA-S submitted for TCAR indication"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103989,"accession_number":"0001493152-26-008894","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"InspireMD dismisses COO Andrea Tommasoli effective April 1, 2026","event_type":"leadership","confidence":"high","bullets":["Andrea Tommasoli, COO, given notice of dismissal on February 27, 2026.","Released from duties effective April 1, 2026; expected last day September 1, 2026.","Will receive base salary through 6-month notice period and benefits up to 12 months.","Severance of approximately €61,000 gross plus accrued untaken paid leave.","No replacement named; termination subject to French labor law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120263,"accession_number":"0001493152-25-028558","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"InspireMD director Kathryn Arnold resigns; company awards ~$140k in accelerated equity and fees","event_type":"leadership","confidence":"high","bullets":["Kathryn Arnold, Class III director, resigns effective Dec 31, 2025; no disagreement with company.","Compensation Committee accelerates unvested equity awards and extends option expiration by two years.","Company to pay three additional quarters of board and committee member fees.","Grant of ~$140k in common stock (75%) and options (25%) at Dec 30 closing fair market value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120262,"accession_number":"0001493152-25-020718","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"InspireMD Q3 revenue record $2.5M (+39% YoY) as U.S. CGuard Prime launch gains traction","event_type":"earnings","confidence":"high","bullets":["U.S. revenue of $497k marks first commercial quarter for CGuard Prime carotid stent system.","Net loss $12.7M ($0.17/share) vs $7.9M ($0.16) a year ago; operating expenses up 57% on U.S. expansion.","Cash and marketable securities $63.4M at Sep 30, up from $34.6M at Dec 31, 2024, boosted by $58M July offering.","Over 100 U.S. carotid procedures completed; appointed Peter A. Soukas, M.D. as CMO and Dan Dearen to board.","Gross profit nearly doubled to $864k on favorable shift toward higher-margin U.S. sales."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":5830000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136849,"accession_number":"0001493152-25-013828","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"InspireMD Appoints Dan Dearen to Board, Replacing Thomas Kester","event_type":"leadership","confidence":"high","bullets":["Thomas Kester resigned as Class III director effective Sept. 16, 2025; no disagreement cited.","Danny Lee Dearen Jr. appointed Class III director, Audit Committee chair, and Compensation Committee member.","Dearen received ~$180K equity grant (75% restricted stock, 25% stock options) vesting in one year.","Kester received accelerated vesting, extended option expiry, and ~$120K in stock/options as separation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136845,"accession_number":"0001493152-25-012805","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K/A","filed_at":"2025-09-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"InspireMD appoints Raymond Cohen to Audit and Compensation Committees","event_type":"other_material","confidence":"high","bullets":["Raymond W. Cohen appointed to Audit Committee and Compensation Committee on September 7, 2025.","Cohen had previously been appointed as a Class 3 director on July 31, 2025.","The Board made the committee assignments after the original 8-K filing; no other changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136848,"accession_number":"0001641172-25-022159","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"InspireMD Q2 net loss widens to $13.2M ($0.26/share); revenue up 2.3% to $1.78M","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.2M ($0.26 per share) vs $7.9M loss ($0.22) in Q2 2024; operating expenses surged 55% to $13.3M.","Revenue of $1.78M, up 2.3% YoY; gross profit fell 5.4% to $313k; cash & securities dropped to $19.4M from $34.6M.","Company raised $58M in gross proceeds from equity private placement and warrant exercise.","FDA granted PMA approval for CGuard Prime carotid stent; US commercial launch commenced; CE Mark under MDR also received.","Appointed Mike Lawless as CFO and added Raymond W. Cohen to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":3307000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136847,"accession_number":"0001641172-25-021675","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"InspireMD raises $58M via PIPE and warrant exercise; appoints Ray Cohen to board","event_type":"other_material","confidence":"high","bullets":["PIPE gross proceeds $40.1M: 16.6M shares/pre-funded warrants at $2.42/share; led by OrbiMed and Marshall Wace.","Warrant exercise yields $17.9M: 12.9M Series I warrants exercised at $1.3827, triggered by FDA PMA of CGuard Prime.","Combined $58M to fund U.S. commercial launch of CGuard Prime; intended use includes sales/marketing, R&D, working capital.","Raymond W. Cohen appointed to Board (Cl. 3), effective Aug 1; former CEO of Axonics (sold to BSX for $3.7B), brings MedTech scaling expertise.","Directors Kathryn Arnold and Thomas Kester will not stand for reelection in 2026; expected resignations by Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136846,"accession_number":"0001641172-25-018302","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"InspireMD launches CGuard Prime carotid stent system in US after FDA PMA approval","event_type":"other_material","confidence":"high","bullets":["U.S. commercial launch of CGuard Prime carotid stent system after FDA PMA approval.","Device features dual-layer design with MicroNet mesh (20 µm PET) and SmartFit technology.","CEO Marvin Slosman notes double-digit market share in >30 countries; U.S. team assembled.","First commercial case performed by Dr. D. Chris Metzger at OhioHealth; Ballad Health involved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154084,"accession_number":"0001641172-25-016293","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"InspireMD receives FDA PMA approval for CGuard Prime carotid stent system; triggers $17.9M warrant tranche","event_type":"regulatory","confidence":"high","bullets":["FDA approved CGuard Prime carotid stent system on June 23, 2025 for stroke prevention in carotid artery stenosis.","Pivotal C-GUARDIANS trial (316 patients) showed lowest 30-day (0.95%) and 1-year (1.93%) major adverse event rates.","FDA approval triggers second warrant tranche; gross proceeds expected $17.9M if exercised in full.","Proceeds to fund U.S. commercial launch, new regulatory pathways, and product development.","Over 65,000 CGuard Prime implants to date; investors include Marshall Wace, OrbiMed, etc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154083,"accession_number":"0001641172-25-014986","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"InspireMD receives CE Mark approval for CGuard Prime EPS under EU MDR","event_type":"regulatory","confidence":"high","bullets":["CE Mark approval under European Medical Device Regulation (MDR) for CGuard Prime Embolic Prevention System.","Product designed with MicroNet mesh to reduce embolic events and prevent stroke.","Approval clears path for commercial launch in current CE-marked served markets.","Same platform intended for US launch later in 2025, subject to FDA approval.","CEO Marvin Slosman highlights regulatory milestone and next-generation platform advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154082,"accession_number":"0001641172-25-013433","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"InspireMD appoints Michael Lawless as CFO, succeeding Craig Shore","event_type":"leadership","confidence":"high","bullets":["Michael Lawless appointed CFO effective on/before June 30, 2025; succeeds Craig Shore who served ~15 years.","Base salary of $375,000 annually, plus performance bonus up to 50% of base salary.","Inducement grant: 212,000 stock options and 465,000 restricted shares, vesting over 3 years under NASDAQ Rule 5635(c)(4).","Employment agreement has 3-year initial term with automatic renewal; severance includes 6 months base salary (non-CIC) or 12 months (CIC).","Lawless previously CFO of Lifeward (LFWD) and held senior finance roles at Azenta, PerkinElmer, and Momenta Pharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154081,"accession_number":"0001641172-25-013427","cik":1433607,"company_name":"InspireMD, Inc.","ticker":"NSPR","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"InspireMD shareholders re-elect Berman and Ward, ratify auditors at 2025 annual meeting","event_type":"other","confidence":"high","bullets":["Directors Berman and Ward re-elected as Class 2 directors: Berman 12,429,779 for, 248,915 withheld; Ward 12,447,235 for, 231,459 withheld; 7,800,113 broker non-votes each.","Ratification of Kesselman & Kesselman as FY2025 independent auditor approved: 20,308,180 for, 164,980 against, 5,647 abstain.","Annual meeting quorum of 66.84% achieved with 20,478,807 shares present out of 30,635,356 outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}